Abstract | BACKGROUND: METHODS: Patients with advanced, unresectable, or metastatic adrenocortical carcinoma with objectively measurable disease or biochemical abnormalities received cisplatin, 50 mg/m(2), intravenously on Days 1 and 2, and etoposide, 100 mg/m(2), on Days 1, 2, and 3. Cycles were repeated every 21 days. At the time of disease progression, patients who had not previously received mitotane received 1000 mg orally 4 times a day along with cortisone acetate and fludrocortisone acetate. RESULTS: Of the 47 patients entered onto the study, 45 were eligible. Nine patients had received mitotane previously and 36 had not. Objective responses were noted in 11% of patients (5 of 45 patients) (95% confidence interval, 3.7-24%). The median survival was 10 months. The most common toxic effects were hematologic, gastrointestinal, and neurologic. Only 16 patients with no prior mitotane therapy went on to receive mitotane at the time of disease progression. An objective response was noted in 13% of patients (2 of 16 patients). The most common toxic effects were edema and gastrointestinal effects. CONCLUSIONS:
|
Authors | S K Williamson, D Lew, G J Miller, S P Balcerzak, L H Baker, E D Crawford |
Journal | Cancer
(Cancer)
Vol. 88
Issue 5
Pg. 1159-65
(Mar 01 2000)
ISSN: 0008-543X [Print] United States |
PMID | 10699907
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2000 American Cancer Society. |
Chemical References |
- Etoposide
- Mitotane
- Cisplatin
|
Topics |
- Adolescent
- Adrenal Cortex Neoplasms
(drug therapy, pathology)
- Adrenocortical Carcinoma
(drug therapy, pathology, secondary)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Child
- Cisplatin
(administration & dosage, adverse effects)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Male
- Middle Aged
- Mitotane
(administration & dosage, adverse effects)
|